- Pure Red-Cell Aplasia and Recombinant Erythropoietin. // New England Journal of Medicine;8/8/2002, Vol. 347 Issue 6, p458
A correction to the article "Pure Red-Cell Aplasia and Recombinant Erythropoietin" that was published in the May 16, 2002 issue is presented.
- Vitreous levels of erythropoietin in patients with macular oedema secondary to retinal vein occlusions: a comparative study with diabetic macular oedema. García-Arumí, J; Fonollosa, A; Macià, C; Hernandez, C; Martinez-Castillo, V; Boixadera, A; Zapata, M A; Simo, R // Eye;Aug2009, Vol. 23 Issue 8, p1754
A correction to the article "Vitreous levels of erythropoietin in patients with macular oedema secondary to retinal vein occlusions: a comparative study with diabetic macular oedema" is presented.
- ERRATUM. // Oncologist;Mar2008, Vol. 13 Issue 3, p347
A correction to the article "The Role of Recombinant Erythropoietin in Childhood Cancer," by Ananth Gouri Shankar that was published in the 2008 issue is presented.
- Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise. Russell, Gabrielle; Gore, Christopher J.; Ashenden, Michael J.; Parisotto, Robin; Hahn, Allan G. // European Journal of Applied Physiology;Apr2002, Vol. 86 Issue 6, p548
Provides a correction to an article about the effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise.
- Full results on risks of epoetin emerge 14 years after study. Epstein, Keith // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;5/26/2012, Vol. 344 Issue 7858, p2
The article reports on a new retrospective study published in the March 2012 issue of the journal "Kidney International" which shows that researchers under-reported serious side effects and overstated the advantages of high doses of the drug epoetin alfa in patients undergoing haemodialysis.
- Correction: Emerging biological roles for erythropoietin in the nervous system. Brines, Michael; Cerami, Anthony // Nature Reviews Neuroscience;Aug2005, Vol. 6 Issue 8, p659
Presents a correction to the article "Emerging biological roles for erythropoietin in the nervous system," by Michael Brines and Anthony Cerami that was previously published in a 2005 issue of "Nature Reviews Neuroscience" journal.
- Tumor necrosis factor a primes cerebral endothelial cells for erythropoietin-induced angiogenesis. Wang, Lei; Chopp, Michael; Teng, Hua; Bolz, Marianne; �lvarez Francisco, Moniche; Aluigi, Danielle Marie; Li Wang, Xin; Zhang, Rui Lan; Chrsitensen, S�ren; Sager, Thomas N; Szalad, Alexandra; Zhang, Zheng Gang // Journal of Cerebral Blood Flow & Metabolism;May2011, Vol. 31 Issue 5, p1334
No abstract available.
- Correction: Erythropoietin Protects Cardiomyocytes from Cell Death during Hypoxia/Reperfusion Injury through Activation of Survival Signaling Pathways. null, null // PLoS ONE;Dec2014, Vol. 9 Issue 12, p1
No abstract available.
- BIOPHARMACEUTICALS: A suggestion of storms ahead. Smith, Adam // Nature Reviews Drug Discovery;Apr2002, Vol. 1 Issue 4, p254
Focuses on recombinant human erythropoietin or epoetin. Role of epoetin in the production of red blood cells; Use of epoetin in the treatment of patients in whom the production of the human hormone erythropoietin is impaired; Degree of specificity; High therapeutic index.